Molecular targets in melanoma: Strategies and challenges for diagnosis and therapy

International Journal of Cancer

Volumn 118, Issue 3, 2006, Pages 523-526

  Herlyn, Meenhard ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Biomarkers; Melanoma; Targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CISPLATIN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NOTCH RECEPTOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; RNA; SCATTER FACTOR; SOMATOMEDIN C; SORAFENIB; STAT PROTEIN;

BIOINFORMATICS; CANCER RESEARCH; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DRUG EFFICACY; DRUG TARGETING; EARLY DIAGNOSIS; GENE AMPLIFICATION; GENE DELETION; HUMAN; MELANOMA; ONCOGENE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

ANIMALS; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 30444432055     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21605     Document Type: Short Survey

References (21)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
2. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
3. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.
4. Bastian BC, Xiong J, Frieden IJ, Williams ML, Chou P, Busam K, et al. Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Am J Pathol 2002;161:1163-9.
5. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
6. Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 2005;121:837-48.
7. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
8. Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, et al. Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 2004;23:2264-74.
9. Smith AP, Weeraratna AT, Spears JR, Meltzer PS, Becker D. SAGE identification and fluorescence imaging analysis of genes and transcripts in melanomas and precursor lesions. Cancer Biol Ther 2004;3:104-9.
10. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004;64:5270-82.
11. Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, et al. Functional proteomic analysis of melanoma progression. Cancer Res 2003;63:6716-25.
12. Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003;63:8103-7.
13. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
14. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65:4320-33.
15. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res, in press.
16. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
17. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 2005;37:745-9.
18. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
19. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001;20:8125-35.
20. Satyamoorthy K, Li G, Vaidya B, Kalabis J, Herlyn M. Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction. Cell Growth Differ 2002;13:87-93.
21. Herlyn M. Metastatic melanoma cells. Introduction. Cancer Metastasis Rev 2005;24:193-4.